Christopher Jackson – CEO & President

Mr. Jackson has over 32 years experience in healthcare sales & marketing, including 25 years of involvement with healthcare start-ups. Mr. Jackson has launched over 35 products during his career, with the majority in the field of women’s health & reproductive medicine.

With experience in product management, healthcare marketing and building and managing successful sales teams, Mr. Jackson is excited about ReceptivaDxTM and the powerful information it provides for women with previously unexplained infertility.

Dan Angress - COO

Mr. Angress has over 30 years experience in diagnostic medicine. He has overseen multiple labs in various executive capacities including business development, marketing, customer service, product management, and operations. His breadth of knowledge in women’s health and reproductive medicine covers a wide range of areas. Mr. Angress serves as the scientific liaison for the company including principal investigator on Cicero’s SBIR NIH grants.

Bruce Lessey, M.D., Ph.D. – Scientific Advisor

Dr. Lessey is the Scientific Advisor for CiceroDx, Inc. and is an internationally recognized leader in uterine receptivity research and the identification of markers associated with unexplained infertility. Dr. Lessey’s extensive research background includes published research on Beta 3 Integrin and BCL6, the two key components of the current ReceptivaDxTM Assay. He has served on multiple editorial boards for major journals and published over 150 peer reviewed articles, with a focus on infertility, endometriosis and the role of the endometrium in embryo implantation.

In addition to his research efforts, Dr. Lessey is a practicing Ob-Gyn at The Fertility Center of the Carolinas in Greenville, SC. Dr. Lessey has been helping women overcome the challenges of infertility for over 3 decades, bringing the key findings of his research into the clinical setting and helping women conceive that had given up hope of ever becoming pregnant.

Board Certification:
American Board of Obstetrics and Gynecology with added qualifications in Reproductive Endocrinology and Infertility

Reproductive Endocrinology and Infertility, Hospital of the University of Pennsylvania

American College of Obstetricians and Gynecologists, American Society of Reproductive Medicine, American Association for the Advancement of Science

Endometriosis, integrins and uterine receptivity, and polycystic ovary disease

David Schammel, M.D. - Pathologist and Partner at Pathology Associates

Dr. David Schammel is the lead pathologist for all ReceptivaDxTM testing for CiceroDx, Inc. . Dr. Schammel, a partner of Pathology Associates in Greenville, SC, has been involved with uterine receptivity testing for over 10 years. Dr. Schammel currently serves as the Medical Director for Pathology Consultants, Inc and is based at the main campus of the Greenville Health System in Greenville, SC.

Board Certification:
Board certified in anatomic and Clinical Pathology

Medical School:
University of Minnesota School of Medicine

University of New Mexico

Surgical pathology fellowship – University of Minnesota

Previous Experience:
Vice Chairman of the Gynecologic and Breast Department of the AFIP in Washington, DC.

Allen M. Gown, MD, Founder & Chief Pathologist, PhenoPath

Dr. Gown received his MD from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY in 1975, and then completed his Pathology Residency as well as Pathology Fellowship training at the University of Washington, Seattle, the latter under the aegis of Dr. Earl Benditt. Dr. Gown rose through the ranks to full Professor of Pathology and served as attending pathologist at the University of Washington Medical Center, where he developed and directed the immunohistochemistry (IHC) laboratory. In 1997, Dr. Gown left the University of Washington to found PhenoPath, which has grown to become an internationally renowned specialty pathology reference laboratory.

Currently, Medical Director and Chief Pathologist at PhenoPath, Dr. Gown is a pathologist-scientist recognized as one of the world’s leading experts in the diagnostic and research applications of IHC. He has developed numerous clinically important monoclonal antibodies employed in IHC laboratories around the world (HMB-45, OSCAR, etc.). Dr. Gown is a member of the editorial boards of many of the major pathology journals. He is a Clinical Professor of Pathology at the University of British Columbia, Vancouver, BC, and an Affiliate Investigator in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA. Dr. Gown continues to be at the forefront of clinical investigative studies employing IHC and other modalities with over 300 peer-reviewed publications and as a frequent presenter at national and international conferences.

The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.

Copyright © 2019 ReceptivaDx™ | All Rights Reserved